5月2日,荣昌生物(09995)早盘股价上涨9.99%,报41.85港元。公司发布2025年第一季度财报,实现营业收入5.26亿元,同比增长59.17%,归母净利润为-2.54亿元。此外,4月8日,公司在第77届美国神经病学会年会上披露了泰它西普治疗全身型重症肌无力的Ⅲ期临床研究结果,进一步推动其创新药物研发进展。免责声明:本文内容由开放的智能模型自动生成,仅供参考。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.